- Will it be possible to administer EGFR inhibitors to patients with early stage non-small cell lung cancer (NSCLC)?
- The real possibility of commercial use of liquid biopsies for patients with stage 1B-3A NSCLC has been confirmed.
SEOUL, Korea, June 14, 2021 (GLOBE NEWSWIRE) — On June 14 GENECAST (CEO, SeungChan Baek), a specialist in liquid biopsy cancer diagnostics, announced that it will initiate a clinical trial for the early diagnosis of non-small cell lung cancer (NSCLC). The team will be led by Professor Jhingook Kim of the Lung and Esophageal Surgery Department of the Thoracic Surgery Department at Samsung Medical Center.
This study evaluates whether the results of liquid biopsy-based EGFR testing using GENECAST’s ADPS technology can represent the results of EGFR testing on tumor tissue DNA. This study is especially important for identifying the clinical effects of liquid biopsies on early cancer detection as it involves early-stage cancer patients in the clinical stages from 1B to 3A.
To date, the clinical effects of liquid biopsies applied to lung cancer patients have mainly been investigated with a focus on lung cancer that has spread systemically through blood. In other words, lung cancer with part of several tumor cells in the blood. On the other hand, little research has been done on the ability to detect EGFR gene mutations before surgery in patients with lung cancer that is resectable due to the absence of lesions that are spread through the blood. Conducting this research is quite difficult.
In recent years, there have been active discussions worldwide about the possibility of investigating pre-operative administration of EGFR inhibitors for resectable early-stage lung cancer. The reason for this is that the preoperative administration of EGFR inhibitors is expected to not only allow surgery by blocking the spread of tumors in early stages and reduce tumor size, but also increase the actual survival rate of patients. In addition, it is easier to administer drugs before surgery. The use of EGFR inhibitors should be preceded by the diagnosis of EGFR gene mutations, but traditional biopsies often carry high risks or are impossible due to the nature of the lung cancer sites.
If the clinical effects of liquid biopsies with ADPS technology demonstrate that this diagnostic method can detect early stage NSCLC, it is expected to lead to more active research efforts on the administration of EGFR inhibitors in these early stage patients.
GENECAST’s chief technical officer (CTO) Byungchul Lee ph.D noted, “With the recent FDA approval of Osimertinib as adjuvant therapy for early stage NSCLC, early diagnosis of this cancer using liquid biopsies is gaining attention. If liquid biopsies can diagnose not only metastatic lung cancer, but also early stage operable lung cancer, they are likely to improve survival rates for NSCLC patients.”
Professor Jhingook Kim, a specialist in lung cancer at the Thoracic Surgery Department of Samsung Medical Center, expressed his hopes for this study: “The study is very important in terms of identifying the effects of liquid biopsies on early-stage patients considering resective surgery for a full recovery, not on patients with systemic metastases. the study results, follow- Studies are likely to be conducted on a variety of topics, such as the use of liquid biopsies in the early diagnosis of cancer.
# Overview of GENECAST
GENECAST is a specialist in cancer diagnosis based on liquid biopsy that analyze cancer genes. This company has achieved 0.01% of the actual detection sensitivity and the highest sensitivity of 0.0001% through its own original technology called the Allele-discriminating priming system (ADPS). ADPS is a qPCR-based technology that enables easier and faster testing than other liquid biopsy-based diagnostic methods. It enables the analysis of cancer genes in stage 1 cancer patients by achieving the highest detection sensitivity currently available. GENECAST operates a range of activities including precision medicine, LDT commercialization and companion diagnostics based on ADPS technology, and is committed to developing new technologies that can realize early diagnosis based on cancer type. More information can be found at www.igenecast.com.
GENECAST Press Agency
Email: [email protected]
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/96d91465-1699-41a3-89f2-6be43bf58df5